PeterJZimetbaumMD
Cardiology • Boston, MACardiac Electrophysiology
Associate Chief and Clinical Director, Cardiology Division Beth Israel Deaconess Medical Center
Dr. Zimetbaum is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
185 Pilgrim Rd
Baker 4
Boston, MA 02215Phone+1 617-632-9209
Summary
- Richard and Susan Smith Professor of Cardiovascular Medicine, Harvard Medical School
Education & Training
Beth Israel Deaconess Medical CenterFellowship, Clinical Cardiac Electrophysiology, 1996 - 1997- Beth Israel Deaconess Medical CenterFellowship, Clinical Cardiac Electrophysiology, 1995 - 1997
- Beth Israel Deaconess Medical CenterFellowship, Cardiovascular Disease, 1993 - 1996
- Beth Israel Deaconess Medical CenterChief Residency, Internal Medicine, 1994 - 1995
- Beth Israel Deaconess Medical CenterFellowship, Cardiovascular Disease, 1993 - 1994
- Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1990 - 1993
- Beth Israel Deaconess Medical CenterInternship, Internal Medicine, 1990 - 1991
Albert Einstein College of MedicineClass of 1990
Certifications & Licensure
MA State Medical License 1992 - 2025- American Board of Internal Medicine Cardiovascular Disease
- American Board of Internal Medicine Clinical Cardiac Electrophysiology
Awards, Honors, & Recognition
- Boston Magazine Castle Connolly, 2012-2013
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011
- Super Doctor SuperDoctors.com
- Join now to see all
Clinical Trials
- Atrial Fibrillation Rate Control Therapy Guided By Continuous Ambulatory Monitoring Start of enrollment: 2005 Apr 01
- Safety Study on Stopping Anticoagulation Medication in Patients With a History of Atrial Fibrillation Start of enrollment: 2013 Jan 01
- Rhythm Evaluation for AntiCoagulaTion With COntinuous Monitoring Start of enrollment: 2012 Oct 01
- Join now to see all
Publications & Presentations
PubMed
- 55 citationsThe association of lactate and vasopressor need for mortality prediction in survivors of cardiac arrest.Michael N. Cocchi, Jared D. Miller, Sabina Hunziker, Erin Carney, Justin D. Salciccioli
Minerva Anestesiologica. 2011-05-11 - 52 citationsComparison of intracardiac echocardiography and transesophageal echocardiography for imaging of the right and left atrial appendagesElad Anter, Joshua R. Silverstein, Cory M. Tschabrunn, Alexei Shvilkin, Charles I. Haffajee
Heart Rhythm. 2014-11-01 - 171 citationsCardiovascular Magnetic Resonance Characterization of Mitral Valve ProlapseYuchi Han, Dana C. Peters, Carol J Salton, Dorota Bzymek, Reza Nezafat
JACC. Cardiovascular Imaging. 2008-05-01
Lectures
- Unmet Need for Rhythm Disturbance After TAVR: Practical Strategies for the Interventional Cardiologist2019 ACC Scientific Session & Expo, New Orleans - 3/17/2019
- Case 4 Debate: Patient With RV Lead and TR: The Extractionist's View2019 ACC Scientific Session & Expo, New Orleans - 3/16/2019
Other
- Risk of QT Interval Prolongation Associated with Use of Hydroxychloroquine with or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Co...Peter Zimetbaum, MD, JAMA Cardiology
https://www.doximity.com/articles/40a5a553-d61c-4d1d-9f58-9aa5e4a77fe2
UpToDate, Wolters Kluwer Health - 2012-11-16 - Prognosis of nonsustained VT in the presence of structural heart diseaseZimetbaum PJ, Wylie JV, Josephson ME
http://www.uptodate.com/contents/prognosis-of-nonsustained-vt-in-the-presence-of-structural-heart-di
UpToDate, Wolters Kluwer Health - 2012-09-21
Authored Content
- Risk of QT Interval Prolongation Associated with Use of Hydroxychloroquine with or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19)May 2020
Press Mentions
Pacemaker Complication Rate Four Times Higher Than ExpectedMay 23rd, 2023- Apixaban Appears Safer, More Effective Than Rivaroxaban in Medicare StudyDecember 27th, 2021
- More Ischemic, Hemorrhagic Events Seen with Rivaroxaban Than ApixabanDecember 22nd, 2021
- Join now to see all
Professional Memberships
- Fellow
- Fellow
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
